BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion

BioMarin announced on December 19, 2025, a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the company at approximately $4.8 billion.123

The deal adds Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease) to BioMarin's portfolio, which generated $599 million in trailing twelve-month revenue.12

Transaction expected to close in Q2 2026, subject to shareholder approval, antitrust clearances, and other conditions; financed with cash and ~$3.7 billion in non-convertible debt.123

Represents a 33% premium to Amicus' closing price on December 18, 2025; anticipated to accelerate revenue growth and be accretive to non-GAAP EPS within 12 months post-close.123

Amicus resolved U.S. patent litigation for Galafold, securing exclusivity until January 30, 2037; includes U.S. rights to Phase 3 asset DMX-200 for focal segmental glomerulosclerosis.12

Sources:

1. https://www.lqventures.com/lucid-diligence-brief-biomarin-to-acquire-amicus-therapeutics-for-4-8b/

2. https://globalgenes.org/raredaily/biomarin-to-acquire-amicus-therapeutics-for-4-8-billion/

3. https://s203.q4cdn.com/846063244/files/docpresentation/2025/12/BioMarin-Business-Update2025-12-19.pdf